Browse F8

Summary
SymbolF8
Namecoagulation factor VIII, procoagulant component
Aliases FVIII; DXS1253E; HEMA; Factor VIIIF8B; hemophilia A; F8C; AHF; DXS1253EB; antihemophilic factor; coagulation ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space.
Domain PF00394 Multicopper oxidase
PF07731 Multicopper oxidase
PF07732 Multicopper oxidase
PF00754 F5/8 type C domain
Function

Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa.

> Gene Ontology
 
Biological Process GO:0002526 acute inflammatory response
GO:0002576 platelet degranulation
GO:0006887 exocytosis
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006900 membrane budding
GO:0006901 vesicle coating
GO:0006903 vesicle targeting
GO:0006953 acute-phase response
GO:0007596 blood coagulation
GO:0007597 blood coagulation, intrinsic pathway
GO:0007599 hemostasis
GO:0016050 vesicle organization
GO:0030168 platelet activation
GO:0045055 regulated exocytosis
GO:0048193 Golgi vesicle transport
GO:0048199 vesicle targeting, to, from or within Golgi
GO:0048207 vesicle targeting, rough ER to cis-Golgi
GO:0048208 COPII vesicle coating
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0072376 protein activation cascade
GO:0072378 blood coagulation, fibrin clot formation
GO:0090114 COPII-coated vesicle budding
Molecular Function GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0005507 copper ion binding
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0005788 endoplasmic reticulum lumen
GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0030133 transport vesicle
GO:0030134 ER to Golgi transport vesicle
GO:0030135 coated vesicle
GO:0030141 secretory granule
GO:0031091 platelet alpha granule
GO:0031093 platelet alpha granule lumen
GO:0031983 vesicle lumen
GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane
GO:0034774 secretory granule lumen
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-204005: COPII (Coat Protein 2) Mediated Vesicle Transport
R-HSA-5694530: Cargo concentration in the ER
R-HSA-140875: Common Pathway of Fibrin Clot Formation
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-140877: Formation of Fibrin Clot (Clotting Cascade)
R-HSA-109582: Hemostasis
R-HSA-140837: Intrinsic Pathway of Fibrin Clot Formation
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-597592: Post-translational protein modification
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolF8
Namecoagulation factor VIII, procoagulant component
Aliases FVIII; DXS1253E; HEMA; Factor VIIIF8B; hemophilia A; F8C; AHF; DXS1253EB; antihemophilic factor; coagulation ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between F8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolF8
Namecoagulation factor VIII, procoagulant component
Aliases FVIII; DXS1253E; HEMA; Factor VIIIF8B; hemophilia A; F8C; AHF; DXS1253EB; antihemophilic factor; coagulation ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of F8 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolF8
Namecoagulation factor VIII, procoagulant component
Aliases FVIII; DXS1253E; HEMA; Factor VIIIF8B; hemophilia A; F8C; AHF; DXS1253EB; antihemophilic factor; coagulation ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of F8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4670.142
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5890.603
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.380.65
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.090.824
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2110.906
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4730.825
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0580.863
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3220.784
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5350.696
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.20.431
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.7040.738
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0960.517
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of F8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.54.114.40.0315
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.55.113.40.102
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.311.82.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.118.24.91
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382718.43.714.70.126
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221322.7022.70.134
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.57.15.41
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolF8
Namecoagulation factor VIII, procoagulant component
Aliases FVIII; DXS1253E; HEMA; Factor VIIIF8B; hemophilia A; F8C; AHF; DXS1253EB; antihemophilic factor; coagulation ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of F8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolF8
Namecoagulation factor VIII, procoagulant component
Aliases FVIII; DXS1253E; HEMA; Factor VIIIF8B; hemophilia A; F8C; AHF; DXS1253EB; antihemophilic factor; coagulation ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of F8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by F8.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolF8
Namecoagulation factor VIII, procoagulant component
Aliases FVIII; DXS1253E; HEMA; Factor VIIIF8B; hemophilia A; F8C; AHF; DXS1253EB; antihemophilic factor; coagulation ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of F8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolF8
Namecoagulation factor VIII, procoagulant component
Aliases FVIII; DXS1253E; HEMA; Factor VIIIF8B; hemophilia A; F8C; AHF; DXS1253EB; antihemophilic factor; coagulation ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of F8 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolF8
Namecoagulation factor VIII, procoagulant component
Aliases FVIII; DXS1253E; HEMA; Factor VIIIF8B; hemophilia A; F8C; AHF; DXS1253EB; antihemophilic factor; coagulation ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between F8 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolF8
Namecoagulation factor VIII, procoagulant component
Aliases FVIII; DXS1253E; HEMA; Factor VIIIF8B; hemophilia A; F8C; AHF; DXS1253EB; antihemophilic factor; coagulation ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting F8 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting F8.
ID Name Drug Type Targets #Targets
DB00055Drotrecogin alfaBiotechCP, F2, F5, F8, GGCX, PF4, PROCR, PROS1, SERPINA5, SERPINB6, SERPI ......12
DB00100Coagulation Factor IX (Recombinant)BiotechF10, F11, F2, F7, F8, GGCX, LRP17
DB12872Vonicog AlfaBiotechCOL1A1, F82
DB13133Von Willebrand Factor HumanBiotechCOL1A1, F82
DB13151Anti-inhibitor coagulant complexBiotechF10, F13A1, F2, F5, F7, F8, FGA, FGB8
DB13152Coagulation Factor IX HumanBiotechF10, F11, F2, F7, F8, GGCX, LRP17
DB13933Nonacog beta pegolBiotechF10, F7, F83